Roflumilast improves lung function after 6 months compared with placebo

October 22nd, 2012 in Medications /

Roflumilast was associated with significant improvements in lung function in patients with moderate and severe chronic obstructive pulmonary disease (COPD) after 6 months of treatment compared with placebo.

Roflumilast is approved to reduce the risk of exacerbations in patients with severe COPD associated with and a history of exacerbations.

To examine the drug's impact on lung function, researchers from multiple institutions, including Baylor College of Medicine; Takeda Pharmaceuticals International GmbH; and Forest Research Institute, randomized 4,746 subjects to roflumilast (pooled intent-to-treat [ITT], n= 2511; moderate COPD, n=1184; severe COPD, n=1217) or placebo (pooled ITT, n=2235; moderate COPD, n=1098; severe COPD, n=1062).

Baseline demographics were similar between treatment groups.

At 6 months, roflumilast increased pre- and postbronchodilator FEV1 by 66 mL and 67 mL, respectively, compared with placebo. Roflumilast, compared with placebo, also increased pre- and postbronchodilator in subjects with moderate and severe COPD.

This study was presented during CHEST 2012, the annual meeting of the , held October 20 – 25, in Atlanta, Georgia.

Provided by American College of Chest Physicians

"Roflumilast improves lung function after 6 months compared with placebo." October 22nd, 2012. http://medicalxpress.com/news/2012-10-roflumilast-lung-function-months-placebo.html